JB Chemicals & Pharmaceuticals Ltd, one of the fastest-growing pharmaceutical companies in India & the leading player in Hypertension, has announced its foray into the area of Nephrology with a new dedicated division called “RENOVA” which will endeavour to serve patients who are under treatment for Chronic Kidney Disease.
The new division will focus exclusively on comprehensive renal care ranging from the management of hypertension in Chronic Kidney Disease to End-stage renal disease. After successfully becoming one of the leading players in Hypertension with brands like Cilacar® and Nicardia®, JBCPL has now begun to also focus on patients with CKD.
Chronic Kidney Disease (CKD) has emerged as a major cause of global morbidity and mortality with the Global Disease Burden report of 2015 labelling it as one of the most common causes of death. There has been a 37.1% rise in mortality over 10 years. In India, the burden of CKD has not been assessed properly, but it is estimated that the prevalence of CKD is 800 patients per million population and the prevalence of end-stage renal disease is 150-200 patients per million population. Unfortunately, only a small portion of CKD patients reach nephrologists and mostly in the later stages when the diseases have progressed. The segment, therefore, needs dedicated intervention.
“Being one of the leaders in the hypertension segment, we realised that Chronic Kidney Disease is a major issue in the country and the numbers are rising significantly. There are growing cases of hypertension associated with CKD and we believe this initiative will enable us to serve the growing unmet needs of CKD patients.” Nikhil Chopra, CEO & Whole Time Director, J.B. Chemicals & Pharmaceuticals Limited, said.
He further added, “JBCPL remains committed to serving the needs of patients and the launch of the dedicated nephrology division is a testament to that fact. Besides the division launch, we will continue to create awareness about CKD and enable patients to reach out to physicians as early as possible.”
With the introduction of this new division and patient-centric initiatives, JBCPL can help address the medical needs of patients with CKD. The launch of this division will also enable nephrologists and physicians to provide patients with different treatment options and ultimately improve the quality of life in these patients. JBCPL will continue to launch products under this division to achieve its objective of providing holistic support to CKD patients at every stage.